CA-ARIBIO
5.1.2023 13:10:39 CET | Business Wire | Press release
AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD). AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.
This study is a randomized, placebo-controlled, double-blind, multi-center Phase 3 trial that plans to enroll 800 participants from approximately 75 sites for 12 months of treatment, followed by an optional two-year extension phase. Patients will be randomly assigned to receive either 30 mg of AR1001 or placebo once daily for 52 weeks. In the optional-extension study, participants originally assigned to placebo will receive 30 mg of AR1001 for an additional two years of treatment. The primary endpoint in the trial is the Change in the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) at Week 52. “As we learn more about Alzheimer’s disease with the understanding that different therapeutic approaches are necessary to demonstrate a meaningful benefit to patients and their caregivers we look forward to data on AR1001,” said Dr. Greeley, CMO for AriBio USA.
“AriBio USA is excited to share this significant milestone, and we look forward to providing regular updates to the program as enrollment progresses in this Phase 3 trial. We continue to engage with interested investigators and sites who are committed to making a difference in the treatment and care of patients with Alzheimer’s disease,” said James Rock, CEO of AriBio USA, Inc. Enrollment is expected to require approximately 2 years for this Phase 3 trial. Dr. Greeley stated, “As we understand more about Alzheimer’s disease, with the understanding that different therapeutics and lifestyle approaches will be necessary to demonstrate a meaningful benefit to patients and their caregivers, we expect AR1001 to be part of this treatment paradigm.”
AriBio Ltd, the parent company of AriBio USA, is committed to developing new therapeutics in the neurology space with a pipeline of PDE-5 inhibitors and other new molecular entities. “Our goal is to transform the treatment options available for patients with dementia to improve their daily lives,” stated Dr. Matthew Choung, CEO of AriBio Ltd.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of therapies for neurodegenerative diseases. AriBio USA, INC. is the subsidiary company of AriBio Co., Ltd. based in San Diego, CA in charge of clinical operations and regulatory affairs for AriBio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Windrose and Autel Validate Real-World Megawatt Charging Under MCS Standard in the Netherlands17.3.2026 09:03:00 CET | Press release
As electric heavy-duty vehicles continue to expand across Europe, charging infrastructure is evolving toward megawatt-level capability. Windrose and Autel Europe recently announced the successful completion of a real-world Megawatt Charging System (MCS) charging session at the Mega Charging Hub of a prime customer of Revolt in Roosendaal, marking an operational validation of charging under the MCS standard in live site conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260313298350/en/ Windrose electric truck charging with Autel’s MCS-enabled megawatt charging system. The deployment features a modular megawatt configuration combining three MaxiCharger DS480 high-power charging cabinets connected in parallel to form a 1,440 kW system. The setup is paired with the MaxiCharger DT1500 MCS-enabled dispenser, capable of delivering up to 1.2 MW output through the MCS interface with a maximum current of 1,500 A, while also s
Aqara Enhances Smart Home Security Lineup with Camera Hub G350, and the Doorbell Camera G400 (Wired)17.3.2026 09:00:00 CET | Press release
Aqara offered a unified, comprehensive home security experience to users with the world’s first Matter-certified camera and the reliable wired camera Aqara, a global leader and pioneer in IoT, today announced the availability of the Camera Hub G350, the world’s first Matter-certified camera, and the Doorbell Camera G400 (Wired), expanding its next-generation smart home security lineup. Together, these new products deliver seamless interoperability, intelligent monitoring, and comprehensive home coverage for the modern smart home. Camera Hub G350: World’s First Matter-Certified Camera and Smart Home Controller The Aqara Camera Hub G350 marks an important milestone for Aqara as the world’s and the company’s first Matter-certified camera. Built to deliver future-ready interoperability, the G350 connects directly to Matter-enabled platforms* while offering live view, two-way audio, and alerts within the Matter-enabled ecosystem. Beyond serving as an indoor security camera, the device also
Yolanthe Cabau Honoured With Lifetime Achievement Award for Her Global Fight Against Child Sexual Exploitation17.3.2026 09:00:00 CET | Press release
The actress, entrepreneur and philanthropist was recognised during UN Commission on the Status of Women Week for nearly two decades of advocacy with her foundation, Free a Girl During the United Nations Commission on the Status of Women Week, actress, entrepreneur and philanthropist, Yolanthe Cabau, was awarded the Lifetime Achievement Award from the New York City Bar Association in recognition of her work combating the sexual exploitation of children. Held in New York, the awards evening emphasised the importance of safety within the justice system, recognising that protecting vulnerable children also requires safeguarding the frontline teams working to create change. As the founder of the anti-child sex trafficking NGO Free a Girl, the Lifetime Achievement Award recognises Cabau’s eighteen years of dedication to rescuing children from sexual exploitation worldwide and supporting their path to justice, recovery, and empowerment. Free a Girl is a women-led organisation working to comba
Mobileum Showcases “Signal to Value” at MWC Barcelona 202617.3.2026 09:00:00 CET | Press release
AI-driven capabilities across roaming, fraud and risk management, network assurance, and enterprise AI help operators turn network events into insight, action, and revenue Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, highlighted its ”Signal to Value” vision at MWC Barcelona 2026, demonstrating how telecom operators can turn network events into insight, action, and revenue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317260292/en/ Mobileum team at MWC Barcelona 2026. At the event, Mobileum demonstrated how operators can leverage its Active Intelligence Platform to enhance roaming performance, strengthen fraud and risk defenses, and automate network assurance across increasingly complex global networks. “Operators generate massive volumes of network events every second, but the real value comes from turning those events into insights, action, and revenue,” said Bernardo Lucas,
SIAL Paris 2026 : the Event That Sheds Light on and Accelerates the Global Food Business17.3.2026 09:00:00 CET | Press release
SIAL Pariswill return to Paris Nord Villepinte from 17 to 21 October 2026. The 2026 edition is set to be the most ambitious in the show’s history, surpassing an already record-breaking 2024 event and further cementing its status as a global benchmark for the food industry. SIAL Paris once again positions itself as a powerful business accelerator, an unparalleled showcase for major innovations and a strategic observatory of the trends shaping the future of food worldwide. With 85% of exhibition space already booked, up to 8,000 exhibitors expected, 295,000 professionals and more than 280,000 m² of exhibition space spanning 10 key sectors, SIAL Paris 2026 confirms both its exceptional international reach and the strong commitment of companies across the entire food value chain. A STRONG COMMERCIAL DYNAMIC AND A HIGHLY INTERNATIONAL SHOW Seven months ahead of opening, SIAL Paris 2026 is already posting strong commercial indicators. More than 260,000 m² of exhibition space has been sold, r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom